Ligand Pharmaceuticals (LGND) traded at $274.88, above the average analyst 12-month target price of $271.00. The note is mainly a technical/analyst-comparison update rather than a fundamental catalyst, though crossing the target may prompt analyst revisions or investor repositioning. The article provides no new earnings, guidance, or clinical data.
Ligand Pharmaceuticals (LGND) traded at $274.88, above the average analyst 12-month target price of $271.00. The note is mainly a technical/analyst-comparison update rather than a fundamental catalyst, though crossing the target may prompt analyst revisions or investor repositioning. The article provides no new earnings, guidance, or clinical data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.12
Ticker Sentiment
